Physician profile
Chen Chen
NPI 1538788401
$793.05
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $203 · 2022: $590.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $259.71 | 2021-2022 | |
| Novo Nordisk INC | $145.81 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $124.97 | 2022 | |
| Lilly USA, LLC | $94.94 | 2022 | |
| Dexcom, INC. | $39.86 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.80 | 2021 | |
| Antares Pharma, INC. | $27.57 | 2021 | |
| Abbvie INC. | $22.30 | 2021 | |
| Horizon Therapeutics Plc | $19.43 | 2022 | |
| Clarus Therapeutics INC. | $13.90 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.76 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chen Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.